1. Home
  2. QCLS vs BCDA Comparison

QCLS vs BCDA Comparison

Compare QCLS & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Q/C Technologies Inc.

QCLS

Q/C Technologies Inc.

HOLD

Current Price

$1.69

Market Cap

14.7M

Sector

Health Care

ML Signal

HOLD

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$1.12

Market Cap

14.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QCLS
BCDA
Founded
2014
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.7M
14.1M
IPO Year
2013
2009

Fundamental Metrics

Financial Performance
Metric
QCLS
BCDA
Price
$1.69
$1.12
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
191.4K
162.2K
Earning Date
04-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
22.33
N/A
EPS
N/A
N/A
Revenue
$3,929,527.00
$479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
32.71
N/A
52 Week Low
$1.76
$0.75
52 Week High
$8.17
$2.27

Technical Indicators

Market Signals
Indicator
QCLS
BCDA
Relative Strength Index (RSI) 23.58 56.90
Support Level N/A $0.78
Resistance Level $3.98 $1.26
Average True Range (ATR) 0.18 0.06
MACD -0.04 -0.00
Stochastic Oscillator 1.73 50.73

Price Performance

Historical Comparison
QCLS
BCDA

About QCLS Q/C Technologies Inc.

Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: